Opening an autophagy window as the apoptosis door starts to close

September 24, 2020

Tokyo - Many people across the globe are working hard to get the better of cancer; however cancer is always working too. Cancer cells can become resistant to the methods that have been adopted to kill them, so identifying drugs that act in different ways is part of the push to outsmart this ubiquitous disease. TMDU researchers have engineered a material that can identify cancer cells and mount an attack that they are not yet ready for. Their findings are published in the Journal of Materials Chemistry B.

Most of the anti-tumor drugs available work by inducing a cell death process known as apoptosis, and unfortunately cancer cells are developing resistance to drugs that work by this mechanism. However, other modes of cell death are known and focusing on alternative mechanisms is one way for researchers to stay a step ahead.

The TMDU researchers previously reported a supermolecule (Me-PRX) that acts as a drug by inducing autophagic cell death. The structure of Me-PRX can be thought of as lots of rings threaded onto a piece of string. These rings are kept on the string by adding stoppers to each end. However, the stoppers are specifically designed so that the rings are released at the acidic pH inside the cell. The release of the rings inside the cell causes endoplasmic reticulum stress, which leads to autophagic cell death.

Me-PRX has significant potential, but until now lacked a way of targeting the specific cancer cells requiring treatment. It was also too small to stay in the bloodstream for extended periods. In their recent work, the researchers have attached their supramolecular drug to the Trastuzumab antibody, which is able to identify the HER2 gene that is overexpressed by many tumor cells.

The size increase brought about by forming this antibody-drug conjugate (ADC) also stops it being filtered out by the kidneys, giving it more time to act. And being larger helps the ADC to be passively taken up by tumors.

"We compared our Trastuzumab-modified Me-PRX (Tras-Me-PRX) with Me-PRX alone and Me-PRX modified with an antibody unable to target HER2-overexpressing cancer cells," study lead author Atsushi Tamura explains. "And we found that the binding of Trastuzumab to HER2 played an important role in getting Me-PRX into cells."

The researchers also found that lower concentrations of Tras-Me-PRX were needed to have an impact on the number of live healthy cells than those required for Me-PRX alone. This shows that the delivery of Tras-Me-PRX led to enhanced autophagic cell death.

"Our demonstration of targeted delivery and cell death using an ADC is a significant step towards an autophagic cell death drug," study corresponding author Nobuhiko Yui explains. "Many ADCs have been approved for clinical use; therefore we are hopeful that future in vivo investigations with our material will ultimately lead to a tangible option in the clinic."
The article, "An antibody-supermolecule conjugate for tumor-specific targeting of tumoricidal methylated β-cyclodextrin-threaded polyrotaxanes", was published in the Journal of Materials Chemistry B at DOI: 10.1039/d0tb00575d.

Tokyo Medical and Dental University

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to